Get the Stockscreener App
20.47
3.12%
0.62
Pre-market:
20.26
-0.21
-1.03%
Urogen Pharma Ltd stock is traded at $20.47, with a volume of 813.49K.
It is up +3.12% in the last 24 hours and up +2.61% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$19.85
Open:
$19.99
24h Volume:
813.49K
Relative Volume:
0.74
Market Cap:
$947.03M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-5.5777
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
+7.91%
1M Performance:
+2.61%
6M Performance:
+75.86%
1Y Performance:
+66.97%
1-Day Range:
$19.73
$20.72
1-Week Range:
$19.00
$21.00
52-Week Range:
$3.42
$21.71
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
20.47 | 918.34M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Using data tools to time your UroGen Pharma Ltd. exitJuly 2025 Volume & Trade Opportunity Analysis - newser.com
Automated trading signals detected on UroGen Pharma Ltd.Market Growth Report & Daily Volume Surge Signals - newser.com
Applying Elliott Wave Theory to UroGen Pharma Ltd.2025 Macro Impact & Free Accurate Trade Setup Notifications - newser.com
Can UroGen Pharma Ltd. stock withstand economic slowdown2025 Earnings Surprises & Daily Technical Stock Forecast Reports - newser.com
Why UroGen Pharma Ltd. (UR8) stock stays on buy listsJuly 2025 Technicals & Entry Point Strategy Guides - newser.com
Does UroGen Pharma Ltd. show high probability of rebound2025 Key Highlights & Capital Protection Trading Alerts - newser.com
UroGen: Expect Rough Patch Before Strong Recovery In 2026 (NASDAQ:URGN) - Seeking Alpha
Is UroGen Pharma Ltd. stock bottoming outPortfolio Growth Summary & Community Verified Trade Signals - newser.com
How UroGen Pharma Ltd. stock reacts to job market dataJuly 2025 Setups & Trade Opportunity Analysis Reports - newser.com
Can UroGen Pharma Ltd. stock resist sector downturnsJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Is UroGen Pharma Ltd. (UR8) stock undervalued after correctionMarket Weekly Review & Intraday High Probability Setup Alerts - newser.com
How UroGen Pharma Ltd. stock compares to industry benchmarks2025 Retail Activity & Free Daily Entry Point Trade Alerts - newser.com
What indicators show strength in UroGen Pharma Ltd.Gold Moves & Safe Capital Allocation Plans - newser.com
How UroGen Pharma Ltd. (UR8) stock behaves in tightening cyclesJuly 2025 Intraday Action & Weekly Chart Analysis and Trade Guides - newser.com
What analysts say about UroGen Pharma Ltd stockPrice Volatility Patterns & High Return Stock Ideas - earlytimes.in
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025 - The Manila Times
Migdal Insurance & Financial Holdings Ltd. Reduces Position in Urogen Pharma $URGN - MarketBeat
Published on: 2025-10-30 00:50:10 - newser.com
UroGen Pharma Hits Day High with 9.46% Surge in Stock Price - Markets Mojo
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Urogen Pharma (URGN) to Release Earnings on Wednesday - MarketBeat
Allianz Asset Management GmbH Invests $203,000 in Urogen Pharma $URGN - MarketBeat
Urogen Pharma (NASDAQ:URGN) Trading 10.1% HigherHere's What Happened - MarketBeat
Is UroGen Pharma Ltd. stock attractive for ETFs2025 Market WrapUp & Stock Market Timing Techniques - fcp.pa.gov.br
HC Wainwright Reaffirms Buy Rating for Urogen Pharma (NASDAQ:URGN) - MarketBeat
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):